Galenica Reports Strong 2025 Results and Raises Mid-Term Guidance

Galenica AG announced robust financial results for 2025, marking a 5.5% sales increase to CHF 4,135.6 million. All business areas contributed to this growth. The company's adjusted EBIT rose by 11.3% to CHF 234.8 million, with net profit from ongoing business operations up by 3.0% to CHF 188.7 million.

Pharmacies expanded their healthcare services, performing over 368,000 consultations, including nearly 93,000 vaccinations. Modernisation of wholesale systems, particularly at the Lausanne-Ecublens site, improved logistics efficiency, with over 70% automation reached.

Galenica acquired Labor Team Group, enhancing its diagnostics offerings and exploring new innovation potential. In light of positive results, the company projects a 5-7% sales growth in 2026 and has raised its adjusted EBIT mid-term guidance to CHF 270 million by 2027.